Evidence map›Paper›PMID 27072858›Full record

ArticleAdvanced healthcare materials2016

Bioactive Anti-Thrombotic Modification of Decellularized Matrix for Vascular Applications.

Jeremy J Glynn, Monica T Hinds

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jeremy J GlynnDepartment of Biomedical Engineering, Oregon Health & Science University, Mail Code: CH13B 3303 SW Bond Ave, Portland, OR, 97239, USA.
Monica T HindsDepartment of Biomedical Engineering, Oregon Health & Science University, Mail Code: CH13B 3303 SW Bond Ave, Portland, OR, 97239, USA.
Oregon Health & Science University · US

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Modified surfaces to capture endothelial progenitor cells for venous applicationsR01HL103728 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI HINDS, MONICA T · 2010 to 2014
$1.9M
NHLBI NIH HHS R01 HL103728NIH HHS P51 OD011092
6 · The paper itself

Abstract

The decellularized matrix derived from porcine small intestinal submucosa (SIS) is a widely used biomaterial being investigated for numerous applications. Currently, thrombus deposition and neointimal hyperplasia have limited the use of SIS in some vascular applications. To limit these detrimental processes, this work applies bioactive, endothelial-inspired properties to the material. SIS is modified with the endothelial cell membrane protein thrombomodulin and the glycosaminoglycan heparin to facilitate protein C activation and anticoagulant activity, respectively. Modifying SIS with thrombomodulin alone enables robust activated protein C (APC) generation, and thrombomodulin activity is maintained after prolonged exposure to fluid shear and blood plasma. Heparin-modified SIS has a potent anticoagulant activity. When both modifications are applied sequentially, SIS modified first with thrombomodulin then with heparin retains the full activity of each individual modification. Tubular SIS devices are connected to a baboon arteriovenous shunt to quantify thrombus deposition on these materials. After being exposed to flowing whole blood for 60 min, SIS devices modified first with thrombomodulin then with heparin have significantly less platelet accumulation compared to unmodified SIS devices. These studies demonstrate that modifying SIS with thrombomodulin and heparin confers APC generation and anticoagulant activity that results in reduced thrombogenesis.

Indexed as

BioprosthesisBlood Vessel ProsthesisAnimalsExtracellular MatrixFibrinolytic AgentsHeparinIntestine, SmallPapioSwineThrombomodulinFibrinolytic AgentsHeparinThrombomodulincoagulationdecellularized biomaterialheparinplateletsthrombomodulin

Identifiers

PMID27072858
PMCPMC5753589
OpenAlexW2339625598

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.